0 citations
Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
The Journal of Clinical Psychiatry2002Vol. 63(12), pp. 1140–1147
Citations Over TimeTop 1% of 2002 papers
Thomas Spencer, John H. Heiligenstein, Joseph Biederman, Douglas E. Faries, Christopher J. Kratochvil, C. Keith Conners, William Z. Potter
Abstract
Two studies of atomoxetine early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD. In addition, atomoxetine was found to be well tolerated.
Related Papers
- → Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label Trial(2002)294 cited
- → A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder(2007)44 cited
- → Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine(2017)33 cited
- → Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study(2023)6 cited